Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: Evidence for normal fibrinolytic state

详细信息    查看全文

• 作者：Ayla Harmanci ; Nurgun Kandemir ; Selcuk Dagdelen ; Nazli Gonc ; Yahya Buyukasik ; Ayfer Alikasifoglu ; Serafettin Kirazli ; Alev Ozon and Alper Gurlek
• 关键词：Thrombin-activatable fibrinolysis inhibitor ; Global fibrinolytic capacity ; Type 1 diabetes ; Complications
• 刊名：Journal of Diabetes and its Complications
• 出版年：2006
• 出版时间：January-February 2006
• 年：2006
• 卷：20
• 期：1
• 页码：40-44
• 全文大小：101 K

文摘

Hypofibrinolysis is a state that is commonly observed in type 2 diabetic patients, a finding also possibly related to obesity and insulin resistance. There is little information, however, regarding the status of fibrinolytic system in Type 1 diabetes, in particular as reflected by thrombin-activatable fibrinolysis inhibitor (TAFI) activity and global fibrinolytic capacity (GFC). To provide information in this respect, 30 Type 1 diabetic patients (median age=16) and 28 healthy controls (median age=14) were enrolled in this study. The median duration of diabetes was 7 years, and median HbA_1c was 8.85 % (range: 5.5–11.9 % ) in the diabetic group. None of the patients had macrovascular complications. Microvascular complications were present in a total of eight patients (nephropathy: n